The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
HOME > BUSINESS
BUSINESS
- Takata Seiyaku to Market 3 Products from Shionogi
June 28, 2012
- MSs Want “Client Visits by MRs” for Generic Promotion: Toho Pharmaceutical Survey
June 27, 2012
- Large Number of GEs Could Become Serious Issue: Alfresa Logistics Chief Fukujin
June 27, 2012
- Takeda to Market Iron Deficiency Anemia Drug in Europe
June 27, 2012
- DSP to Ship Almarl under New Brand Name from Mid-July
June 27, 2012
- Azilva Ranks No. 1 Both in GP, HP Market in May: Rep Track Survey
June 27, 2012
- Astellas Launches Kiklin Capsules, Copromotes with SKK
June 26, 2012
- ACE Inhibitors Approved for Pediatric Use: MSD, AZ, Shionogi, Kyowa Pharmaceutical
June 26, 2012
- Amlodipine Besylate Approved for Supplemental Indication of Pediatric Hypertension, Generic Versions also Approved
June 26, 2012
- Pfizer Remains Top, Takeda Ranks 12th in World Ranking in FY2011
June 26, 2012
- EvaluatePharma Forecasts Januvia to Become World’s Best-Selling Product in 2018
June 25, 2012
- RaQualia Receives Substance Patent Evaluation in US for 5-HT2B Antagonist
June 25, 2012
- Otsuka, UCB Japan Apply for E Keppra for Pediatric Epilepsy
June 25, 2012
- GSK, DSP Launch Paxil CR Tablets
June 25, 2012
- Nexium Approved for Prevention of GU and DU in Patients Receiving Low-Dose Aspirin: Daiichi Sankyo, AZ
June 25, 2012
- Lyrica Approved for Pain Associated with Fibromyalgia: Pfizer Japan
June 25, 2012
- Two Generic Drug Makers Offer Different Views on Impact of Generic Name-based Prescriptions
June 22, 2012
- Ratio of Generic Name Prescribing Up 30% in 2 Doctor Surveys
June 22, 2012
- Takeda Files MAAs for 2 Fixed-Dose Alogliptin Combination Drugs in Europe
June 21, 2012
- Takeda to Terminate Development of Anti-HGF Antibody; Return Rights to Galaxy of the US
June 21, 2012
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…